Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine TTS in Post-Herpetic Neuralgia
NCT00478179Phase 2Completed
- Sponsor
- DURECT Corporation
- Start
- Sep 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Eladur in postherpetic neuralgia (PHN) (2 arms), sponsored by DURECT Corporation. Primary endpoint: Reduction of pain with mean daily pain intensity. Started Sep 2006; status: completed.
02
Drugs
Eladur
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT00478179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478179.